ALTUVIIIO Gets Patent Extension Nod: Biotech Bureaucracy Alert
Published Date: 6/20/2025
Notice
Summary
The FDA has officially set the review period for ALTUVIIIO, a human biological product, so its patent can be extended. This means the company behind ALTUVIIIO gets more time to protect their invention and keep competitors at bay. If you’re in the business of making or selling similar products, this update could affect when new versions hit the market and how long the original patent lasts.
Analyzed Economic Effects
1 provisions identified: 0 benefits, 0 costs, 1 mixed.
ALTUVIIIO Patent Extension Determined
The FDA has set the official regulatory review period for ALTUVIIIO, a human biological product, which allows the patent holder to seek an extension of its patent. If you make or sell similar biological products, this can give the original company more time to keep competitors from selling similar versions and may delay when others can enter the market.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Take It Personal
Get Your Personalized Policy View
Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in